title: How much to worry about the FDA warning in the use of citalopram?
abstract: A number of studies have suggested that antidepressants such as selective serotonin reuptake inhibitors may increase a risk of developing harmful cardiac adverse event such as QT interval prolongation. In fact, the US Food and Drug Administration (FDA) consecutively gave safety warnings to healthcare professionals that the use of citalopram may be associated with QT interval prolongation in 2011 and 2012. Despite the fact that citalopram has been one of the most acceptable antidepressants worldwide, concerns on citalopram about cardiac safety issues have become apparent to clinicians after the FDA warning. However, a recent cohort study raises some practical questions about the FDA warnings on the use of citalopram and may also provide clinicians with a good guidance for prudent use of citalopram in clinical practice.
authors: Department of Psychiatry, The Catholic University of Korea College of Medicine, Seoul, Republic of Korea.
authors: Sheng-Min
authors: SM
authors: Wang
authors: Chi-Un
authors: CU
authors: Pae
mesh_terms: D018687:Antidepressive Agents, Second-Generation / Q000009:adverse effects*; D001145:Arrhythmias, Cardiac / Q000139:chemically induced*; D015283:Citalopram / Q000009:adverse effects*; D006801:Humans; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D018687:Antidepressive Agents, Second-Generation; D015283:Citalopram